Anuj Jain, MD
Cardiovascular Disease · Lincoln, NENPI 1295821585
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,119 of the $1,319 with a category attached, or 84.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $409 and has fallen 67.9% since, to $132 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NE, where the typical reported total is $1,663.
Across 74 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$200
- Sanofi-aventis U.S. LLC$198
- Pfizer$152
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$134
- Cvrx, Inc.$123
- Merck$75
- plus $438 from 15 others
Across 26 payments — averaging $3393.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$59K
- Cvrx, Inc.$12K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Vifor (international) Ltd.$8K
What the payments were for
- Speaking & faculty fees$20015%
- Food & beverage$1,11985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 1 | $200 |
| Sanofi-aventis U.S. LLC | 14 | $198 |
| Pfizer | 11 | $152 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $134 |
| Cvrx, Inc. | 1 | $123 |
| Merck | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Boehringer Ingelheim | 5 | $67 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Heartflow, Inc. | 1 | $42 |
| Boston Scientific | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $29 |
| Amgen | 1 | $24 |
| Medtronic | 1 | $24 |
| Edwards Lifesciences | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Gilead | 1 | $16 |
| Novartis | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- Barostim Neo System$123
How this compares
$1,319 in reported general payments places this provider in the 40th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 312 | $240,751 |
| XareltoRivaroxaban | 152 | $130,411 |
| Repatha SureclickEvolocumab | 100 | $60,327 |
| EntrestoSacubitril/Valsartan | 52 | $51,453 |
| JardianceEmpagliflozin | 42 | $32,886 |
| Praluent PenAlirocumab | 32 | $19,090 |
| Repatha SyringeEvolocumab | 28 | $16,046 |
| FarxigaDapagliflozin Propanediol | 11 | $8,526 |
| Metoprolol Succinate | 726 | $7,328 |
| Ranolazine ErRanolazine | 49 | $3,616 |
| Flecainide Acetate | 95 | $3,203 |
| Bisoprolol Fumarate | 104 | $2,776 |
| Atorvastatin Calcium | 269 | $2,330 |
| Amlodipine Besylate | 448 | $2,000 |
| Nebivolol Hcl | 25 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $240,751312 claims |
| Johnson & JohnsonXarelto | $13 | $130,411152 claims |
| NovartisEntresto | $14 | $51,45352 claims |
| Boehringer IngelheimJardiance | $67 | $32,88642 claims |
| AstraZenecaFarxiga | $13 | $8,52611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Lincoln
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Keith MillerLincoln$86K
- Wynn HunterLincoln$46K
- Gina MentzerLincoln$27K
- Rajeev AnchanLincoln$7K
- Kaliprasad AyalaLincoln$5K
- John SteuterLincoln$4K
- Rebecca RundlettLincoln$3K
- Omar NassLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.